Literature DB >> 9239668

Studies on the relative in-vitro biological potency of the naturally-occurring isoforms of intrapituitary follicle stimulating hormone.

E Zambrano1, J Barrios-de-Tomasi, M Cárdenas, A Ulloa-Aguirre.   

Abstract

In the present study, we analysed and compared the relative in-vitro biological activity of the various intrapituitary human follicle stimulating hormone (FSH) isoforms employing two different bioassay systems. FSH was fractionated by chromatofocusing (pH range 7.10 to < 3.80) and the several isoforms isolated were quantified at multiple dose levels by three highly specific immunoassay systems: radioimmunoassay (RIA), enzyme-immunoassay (EIA) and immunoradiometric assay (IRMA), as well as by two in-vitro bioassays, one that measures the amount of oestrogen produced by rat granulosa cells in culture and the other that determines the amount of cAMP produced by a human fetal cell line (293) expressing the recombinant human FSH receptor. The relative in-vitro biological activity of each FSH isoform, expressed as the bioassay/ immunoassay (B/I) activity ratio (B/RIA, B/EIA and B/IRMA ratios) varied with its elution pH value. Regardless of the immunoassay or bioassay method employed, less acidic FSH isoforms exhibited higher B/I ratios than their more acidic counterparts [B/RIA, B/EIA and B/IRMA ratios for isoforms with elution pH values > 4.5 = 1.05 +/- 0.13, 0.99 +/- 0.10 and 1.15 +/- 0.08 (rat oestrogen bioassay), and 2.75 +/- 0.34, 2.20 +/- 0.25 and 2.96 +/- 0.35 (human cAMP production bioassay) respectively. Ratios for isoforms with pH values < 4.5 = 0.71 +/- 0.06, 0.47 +/- 0.05 and 0.63 +/- 0.06 (rat oestrogen assay), and 1.80 +/- 0.26, 1.10 +/- 0.09 and 1.44 +/- 0.13 (cAMP assay) respectively (P < 0.05 for isoforms with pH < 4.5 compared with those isoforms with pH > 4.5)]. Furthermore, statistically significant direct relationships between the B/RIA, B/EIA and B/IRMA ratios and elution pH value of each isoform was identified by regression analysis [rat assay: r = 0.844, 0.800 and 0.780 (P < 0.01); human assay: r = 0.730, 0.845 and 0.821 (P < 0.01), for their corresponding B/RIA, B/EIA and B/IRMA ratios respectively]. The finding of significant differences in relative in-vitro biological potency among the various intrapituitary FSH isoforms strongly suggests that the shifts towards the production and secretion of more basic or acidic FSH molecules occurring in certain specific physiological conditions (e.g. puberty and menstrual cycle), may represent an important mechanism through which the anterior pituitary regulates gonadal function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9239668     DOI: 10.1093/molehr/2.8.563

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  9 in total

1.  Efficacy of a combined protocol of urinary and recombinant follicle-stimulating hormone used for ovarian stimulation of patients undergoing ICSI cycle.

Authors:  Arianna Pacchiarotti; Cesare Aragona; Renzo Gaglione; Helmy Selman
Journal:  J Assist Reprod Genet       Date:  2007-07-26       Impact factor: 3.412

2.  Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems: implications for the structure-function relationship of the FSH variants.

Authors:  E Zambrano; T Zariñán; A Olivares; J Barrios-de-Tomasi; A Ulloa-Aguirre
Journal:  Endocrine       Date:  1999-04       Impact factor: 3.633

3.  Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys.

Authors:  Teresa Zariñán; Marco A Perez-Solís; Guadalupe Maya-Núñez; Patricia Casas-González; P Michael Conn; James A Dias; Alfredo Ulloa-Aguirre
Journal:  Mol Cell Endocrinol       Date:  2010-03-04       Impact factor: 4.102

4.  Dynamic tests and FSH biological activity in female rats with acute nephrotic syndrome.

Authors:  María Guadalupe Ortiz-López; Mario Cárdenas; Teresa Zariñán; Laura Díaz-Bonilla; Elena Zambrano; José Pedraza-Chaverrí; Marta Menjívar
Journal:  Mol Cell Biochem       Date:  2003-03       Impact factor: 3.396

5.  Single-molecule analyses of fully functional fluorescent protein-tagged follitropin receptor reveal homodimerization and specific heterodimerization with lutropin receptor.

Authors:  Joseph E Mazurkiewicz; Katharine Herrick-Davis; Margarida Barroso; Alfredo Ulloa-Aguirre; Barbara Lindau-Shepard; Richard M Thomas; James A Dias
Journal:  Biol Reprod       Date:  2015-03-11       Impact factor: 4.285

6.  Role of Cysteine Residues in the Carboxyl-Terminus of the Follicle-Stimulating Hormone Receptor in Intracellular Traffic and Postendocytic Processing.

Authors:  Brenda Melo-Nava; Patricia Casas-González; Marco A Pérez-Solís; Jean Castillo-Badillo; José L Maravillas-Montero; Eduardo Jardón-Valadez; Teresa Zariñán; Arturo Aguilar-Rojas; Nathalie Gallay; Eric Reiter; Alfredo Ulloa-Aguirre
Journal:  Front Cell Dev Biol       Date:  2016-07-20

7.  Molecular dynamics simulation of the follicle-stimulating hormone receptor. Understanding the conformational dynamics of receptor variants at positions N680 and D408 from in silico analysis.

Authors:  Eduardo Jardón-Valadez; Derik Castillo-Guajardo; Iván Martínez-Luis; Rubén Gutiérrez-Sagal; Teresa Zariñán; Alfredo Ulloa-Aguirre
Journal:  PLoS One       Date:  2018-11-21       Impact factor: 3.240

8.  In Vitro Impact of FSH Glycosylation Variants on FSH Receptor-stimulated Signal Transduction and Functional Selectivity.

Authors:  Teresa Zariñán; Viktor Y Butnev; Rubén Gutiérrez-Sagal; José Luis Maravillas-Montero; Iván Martínez-Luis; Nancy R Mejía-Domínguez; Guillermo Juárez-Vega; George R Bousfield; Alfredo Ulloa-Aguirre
Journal:  J Endocr Soc       Date:  2020-02-18

9.  Basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution and in vitro biological-to-immunological ratio in male puberty.

Authors:  A Olivares; D Söderlund; C Castro-Fernández; T Zariñán; Elena Zambrano; J P Méndez; A Ulloa-Aguirre
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.